Who is sponsoring NCT03391791?

NCT03391791 is sponsored by Adaptimmune.

What drugs are being tested in NCT03391791?

Interventions in NCT03391791: Genetically engineered T Cell Receptors.

What condition does NCT03391791 study?

NCT03391791 studies Solid and Hematological Malignancies.

Is NCT03391791 still recruiting?

NCT03391791 is currently terminated. Last updated 7 January 2021.

Last reviewed 2021-01-07 · How we verify

NCT03391791

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors

Terminated Last updated 7 January 2021

What this trial tests

trial testing Genetically engineered T Cell Receptors in Solid and Hematological Malignancies in 2 participants. Terminated before completion.

Timeline

28 February 2018

Primary endpoint
24 July 2018

24 July 2018

Quick facts

Lead sponsor	Adaptimmune
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	2
Start date	28 February 2018
Primary completion	24 July 2018
Estimated completion	24 July 2018
Sites	3 locations across Canada, United States

Drugs / interventions tested

Genetically engineered T Cell Receptors

Conditions studied

Solid and Hematological Malignancies — all drugs for Solid and Hematological Malignancies →

Sponsor

Adaptimmune — full company profile →

Who can join

18 and older, any sex, with Solid and Hematological Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Subjects who previously took part in an Adaptimmune study and received genetically changed T cells (including but not limited to MAGE-A10ᶜ⁷⁹⁶T and MAGE-A4ᶜ¹º³²T) are asked to take part in this long term follow-up study. Subjects will be asked to join this study once they complete the parent interventional study. The purpose of this study is to find out if the genetically changed T cells that subjects received in the parent study have any long-term side effects. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years starting from last administration of the genetically changed T cells, subjects will visit their study doctor for a check-up and to have blood tests to look for any changes that might have happened because of the genetically changed T cells.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Engineered T Cell Therapy for Cancer in the Clinic.
Zhao L, Cao YJ. · · 2019 · cited 275× · PMID 31681259 · DOI 10.3389/fimmu.2019.02250
T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.
Sharma P, Kranz DM. · · 2019 · cited 5× · PMID 31679251 · DOI 10.1615/critrevimmunol.2019030788

Verify or expand the search:

Other Adaptimmune trials

Trials by the same sponsor.

NCT04752358 — ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) · Phase 2 · terminated
NCT06048705 — Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Lipo · Phase 1 · terminated
NCT04526509 — Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or L · Phase 1 · terminated
NCT05943990 — Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma · Phase 1 · terminated
NCT03132792 — AFPᶜ³³²T in Advanced HCC · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03391791 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Adaptimmune
Last refreshed: 7 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03391791.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing